MS Treatment Choices: What Matters for Slow Worsening

Credibility

Interest

Share:2 min read

Key Takeaway

In this study, four common MS treatments showed no clear difference in the risk of disability getting worse without an attack.

What They Found

Researchers looked at records of people with relapsing MS who had used one of four treatments for at least five years. They tracked disability that got worse and stayed worse for at least 12 months, even though the person had no MS attack, also called a relapse. They compared two pills, dimethyl fumarate and teriflunomide, and two injections, interferon beta and glatiramer acetate. Within each pair, neither treatment showed a clear advantage in preventing this kind of worsening. Comparing the pills as a group with the injections also showed no clear difference.

Who Should Care and Why

This matters to people with relapsing MS because symptoms or abilities can worsen even when they have not had an attack. If that happens to you, tell your MS care team rather than waiting for another attack. For people choosing among these treatments, the findings suggest that side effects and how well a treatment fits daily life may matter more than an expected difference in this kind of worsening. Caregivers can help by noticing lasting changes in walking or other everyday activities and sharing them at appointments. You and your clinician can use this information to discuss which treatment is safest and easiest for you to keep taking.

Important Considerations

The researchers used past medical records rather than assigning treatments at random, so differences between patients may have affected the results. Finding no clear difference does not prove that the treatments work equally well for every person. The study only included people who stayed on one of these treatments for at least five years, so its findings may not apply to someone starting treatment or changing it sooner.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression Living with MS MS Diagnostics

Article Topics:

Dimethyl fumarateFirst-line therapiesGlatiramer acetateInterferon betaMultiple sclerosisProgression Independent of Relapse ActivityTeriflunomide

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News